UNSPSC 51411615: Oxyfedrine hydrochloride

This classification denotes a vasodilating agent and beta-adrenergic agonist with the molecular formula C19H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63CF9XK7DA, chemically known as 1-propanone, 3-((2-hydroxy-1-methyl-2-phenylethyl)amino)-1-(3-methoxyphenyl)-, hydrochloride but more generally known as oxyfedrine hydrochloride, which bears US NIH Compound Identifier 27972.

UNSPSC 51411615 Oxyfedrine hydrochloride is a Commodity code covering a specific pharmaceutical active ingredient used in emergency medical and acute care settings. State and local governments procure oxyfedrine hydrochloride as part of broader Advanced Life Support medication portfolios purchased by fire-rescue departments, emergency medical services, and health system procurement offices. The work involves supplying pharmaceutical-grade active ingredients or finished formulations to municipal and county emergency response agencies and state health authorities, with strict compliance requirements around potency, sterility, expiration dating, and regulatory certification (cGMP, DSCSA, FDA approval). Issuing bodies include municipal purchasing departments on behalf of fire-rescue operations, state health and human services agencies, and cooperative purchasing alliances spanning multiple state and local jurisdictions.

Recent activity centers on Florida and Minnesota, with a standout Texas state health authority engagement. The City of Tampa's Purchasing Department issued IFB 26P00188 (posted April 24, 2026, due April 8, 2026) for Advanced Life Support Medications including epinephrine, labetalol, adenosine, and diltiazem totaling an estimated $40,000 for Tampa Fire Rescue; this solicitation carried a 5 percent SLBE bid discount and required nine-month minimum shelf life and ten-day delivery. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products across Minnesota, Oregon, and participating member jurisdictions, with wholesaler distribution through Cencora, Cardinal Health, and Morris & Dickson effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription procurement capabilities, signaling potential future competitive procurements in the broader pharmaceutical supply chain. Recent opportunities emphasize price competitiveness, regulatory compliance documentation, and supply chain resilience through authorized wholesaler networks.